Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.76 |
| ▸ | PGR | P06401 | 2/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069452 | 1.00 | ESR1 (0.76) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL5069457 | 1.00 | ESR1 (0.76) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL5124519 | 0.94 | ESR1 (0.68) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL5124515 | 0.94 | ESR1 (0.68) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL5124512 | 0.94 | ESR1 (0.68) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL23851086 | 0.87 | ESR1 (1.00) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL5818558 | 0.87 | ESR1 (1.00) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL5354177 | 0.87 | ESR1 (1.00) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL7723356 | 0.87 | ESR1 (1.00) | ESR1ESR2CYP19A1PGRPTGS2 | |
| SCHEMBL639225 | 0.87 | ESR1 (1.00) | ESR1ESR2CYP19A1PGRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442833-B2 | Triphenylethylene compounds as selective estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1692127-B1 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070111971-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-17 | — | — | US | disclosed |
| EP-1692127-A2 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005033056-A2 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111971-A1 | Novel compounds | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885CYP19A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.